# Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

> **NCT00417248** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nasser Hanna, M.D.** · enrollment: 8 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **PROCEDURE:** Radiotherapy
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00417248
- **Lead sponsor:** Nasser Hanna, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Negative sorafenib results from ESCAPE trial and safety concerns of regimen
- **Last updated:** 2016-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417248, "Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00417248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*